Jiangsu Yahong Meditech News

Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration

Nov 5 11:00 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (November 5, 2024)

Nov 5 03:59 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (October 30, 2024)

Oct 30 23:35 ET

Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on holding a performance briefing for the third quarter of 2024

Oct 29 12:00 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the FDA

Oct 24 12:00 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (October 22, 2024)

Oct 24 05:52 ET

Yahong Pharmaceutical: Corrective Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the Resolutions of the 11th Meeting of the 2nd Board of Directors

Sep 29 12:00 ET

Correction Notice of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on Resolutions of the 11th Meeting of the Second Board of Directors

Sep 29 12:00 ET

Independent Financial Advisory Report of Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd. on matters relating to the granting of the 2024 Restricted Stock Incentive Plan by Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Sep 27 12:00 ET

Announcement of Resolutions of the 11th Meeting of the Second Board of Directors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Sep 27 12:00 ET

Announcement of Resolutions of the 7th Meeting of the 2nd Board of Supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Sep 27 12:00 ET

Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the results of the Phase II clinical trial of APL-1202 oral combined with tirelizumab as a new adjuvant treatment for muscle-invasive bladder cancer

Sep 25 12:00 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Table_2024 Semi-Annual Results Briefing

Sep 20 05:01 ET

CITIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Sep 19 12:00 ET

Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 International Multi-Center Phase III Clinical Trial at the 2024 International Photodynamic and Photodiagnostic Conference

Sep 17 12:00 ET

Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (September 2, 2024)

Sep 3 02:35 ET

Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on publicly soliciting delegated voting rights for independent directors

Sep 2 12:00 ET

Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on holding the 2024 semi-annual results briefing

Sep 2 12:00 ET

CITIC Securities Co., Ltd.\'s inspection opinions on changes to some fund-raising investment projects of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Aug 30 12:00 ET

Announcement of Resolutions of the 6th Meeting of the 2nd Board of Supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

Aug 30 12:00 ET